The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.

Executive Summary and Global Market Analysis

The global cancer therapeutics market is experiencing robust growth, driven by the increasing incidence of breast and lung cancer and heightened investment in oncology research. Cancer therapeutics encompass a wide spectrum of treatments designed to manage or cure cancer. Primary treatment modalities frequently employed include chemotherapy, radiation, immunotherapy, targeted therapy, hormone therapy, surgical interventions, and stem cell therapy. Each of these strategies aims to eradicate or control cancer cells, alleviate symptoms, and enhance patient survival. Treatment often involves a multi-therapy approach, tailored to the specific cancer type and stage, as well as the patient's overall health, to maximize effectiveness.

Cancer Therapeutics Market Segmentation Analysis

The cancer therapeutics market is segmented for analysis by therapy type, indication, and distribution channel.

By therapy type, the market is divided into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other forms of therapy. Chemotherapy held the largest market share in 2024.

For indications, the market includes segments such as blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. Lung cancer accounted for the largest market share in 2024.

Regarding distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies maintained the largest market share in 2024.

Cancer Therapeutics Market Drivers and Opportunities

The World Health Organization reports that approximately 1 in every 6 deaths globally is due to various types of cancer. In 2022, an estimated 20 million new cancer cases and 9.7 million deaths were recorded; this burden is projected to rise by approximately 77% by 2050, placing further strain on health systems and communities. The American Cancer Society indicates that 5–10% of all cancers are inherited. Numerous cancer predisposition genes have been identified. For example, mutations in inherited cancer predisposition genes like BRCA1 and BRCA2 elevate the risk of developing various cancers, including breast, ovarian, and prostate cancer. Breast cancer is considered the most prevalent cancer among women worldwide, with a consistently rising incidence attributed to risk factors such as environmental impact, genetic susceptibility, hormone imbalances, and lifestyle changes. Additionally, breast cancer is among the most prevalent cancers in the U.S.

Cancer Therapeutics Market Size and Share Analysis

Considering therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. Chemotherapy drugs exert their cytotoxic effects by disrupting the growth of cells. These drugs circulate throughout the body in the bloodstream, hindering cancer cell proliferation. The National Institutes of Health estimates that roughly 650,000 cancer patients in the US receive chemotherapy annually in oncology clinics.

In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00031299

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications